31st Mar 2015 11:21
LONDON (Alliance News) - GW Pharmaceuticals PLC said Tuesday that it has begun the phase III part of its phase II/III clinical trial for Epidiolex for the treatment of rare treatment-resistant childhood epilepsy Dravet syndrome.
GW expects to begin the second phase III trial in Dravet syndrome soon after the first trial, which will run in parallel with this phase II/III trial. It also expects to begin two phase III trials in Lennox-Gastaut syndrome early in the second quarter of 2015.
"GW is dedicated to developing Epidiolex for Dravet syndrome as rapidly as possible. As such, the start of the first Dravet syndrome Phase 3 trial is a significant milestone for our Company and we are on track to start the second Phase 3 trial very shortly," said Chief Executive Justin Gover in a statement
Shares in GW are trading up 5.1% at 519.75 pence Tuesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L